SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
NCT07710248
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Immune Thrombocytopenia
Interventions
DRUG:
low dose group
DRUG:
high dose group
DRUG:
Placebo group
Sponsor
Hangzhou Sumgen Biotech Co., Ltd.